Development of Human ILCs and Impact of Unconventional Cytotoxic Subsets in the Pathophysiology of Inflammatory Diseases and Cancer.

ILC-poiesis cancer cytotoxicity inflammation innate lymphoid cells (ILCs) natural killer (NK) cells unconventional subsets

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2022
Historique:
received: 06 04 2022
accepted: 28 04 2022
entrez: 20 6 2022
pubmed: 21 6 2022
medline: 22 6 2022
Statut: epublish

Résumé

Innate lymphoid cells (ILCs) were firstly described by different independent laboratories in 2008 as tissue-resident innate lymphocytes mirroring the phenotype and function of T helper cells. ILCs have been subdivided into three distinct subgroups, ILC1, ILC2 and ILC3, according to their cytokine and transcriptional profiles. Subsequently, also Natural Killer (NK) cells, that are considered the innate counterpart of cytotoxic CD8 T cells, were attributed to ILC1 subfamily, while lymphoid tissue inducer (LTi) cells were attributed to ILC3 subgroup. Starting from their discovery, significant advances have been made in our understanding of ILC impact in the maintenance of tissue homeostasis, in the protection against pathogens and in tumor immune-surveillance. However, there is still much to learn about ILC ontogenesis especially in humans. In this regard, NK cell developmental intermediates which have been well studied and characterized prior to the discovery of helper ILCs, have been used to shape a model of ILC ontogenesis. Herein, we will provide an overview of the current knowledge about NK cells and helper ILC ontogenesis in humans. We will also focus on the newly disclosed circulating ILC subsets with killing properties, namely unconventional CD56

Identifiants

pubmed: 35720280
doi: 10.3389/fimmu.2022.914266
pmc: PMC9204637
doi:

Substances chimiques

Antineoplastic Agents 0

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

914266

Informations de copyright

Copyright © 2022 Calvi, Di Vito, Frigo, Trabanelli, Jandus and Mavilio.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

J Leukoc Biol. 2020 Aug;108(2):723-737
pubmed: 32017245
Front Immunol. 2019 Aug 02;10:1812
pubmed: 31428098
J Immunol. 2010 Oct 1;185(7):3913-8
pubmed: 20802153
Nat Immunol. 2015 Feb;16(2):161-9
pubmed: 25531830
Cell. 2014 Apr 10;157(2):340-356
pubmed: 24725403
Proc Natl Acad Sci U S A. 2021 Dec 14;118(50):
pubmed: 34880136
Cell Mol Immunol. 2021 Feb;18(2):484-486
pubmed: 33318627
Immunity. 2010 Jun 25;32(6):803-14
pubmed: 20620944
Nat Immunol. 2019 Sep;20(9):1150-1160
pubmed: 31358996
Immunity. 2013 Sep 19;39(3):622-622.e1
pubmed: 24012419
Nature. 2010 Apr 29;464(7293):1367-70
pubmed: 20200518
Nat Rev Immunol. 2020 Sep;20(9):552-565
pubmed: 32107466
Immunity. 2019 Apr 16;50(4):1054-1068.e3
pubmed: 30926235
Nature. 2014 Apr 17;508(7496):397-401
pubmed: 24509713
Sci Immunol. 2022 Apr 8;7(70):eabi8642
pubmed: 35394814
Haematologica. 2018 Aug;103(8):1390-1402
pubmed: 29700172
J Clin Invest. 2012 Apr;122(4):1403-15
pubmed: 22378041
Nat Immunol. 2016 Mar;17(3):269-76
pubmed: 26779601
Eur J Immunol. 2011 Nov;41(11):3340-50
pubmed: 21830211
Nat Immunol. 2011 Jan;12(1):21-7
pubmed: 21113163
J Leukoc Biol. 2019 Jun;105(6):1243-1251
pubmed: 30645023
J Immunol. 2019 Jan 1;202(1):171-182
pubmed: 30504420
Science. 2015 Nov 20;350(6263):981-5
pubmed: 26472762
Cell Rep. 2016 Jul 12;16(2):379-391
pubmed: 27373165
Cold Spring Harb Perspect Biol. 2015 Jan 08;7(5):
pubmed: 25573713
Science. 2011 Jan 7;331(6013):44-9
pubmed: 21212348
Cell. 2020 Feb 20;180(4):749-763.e13
pubmed: 32059780
J Immunol. 1983 Oct;131(4):1789-96
pubmed: 6225799
Nat Rev Immunol. 2013 Feb;13(2):145-9
pubmed: 23348417
Blood. 2006 Dec 1;108(12):3824-33
pubmed: 16902150
Oncoimmunology. 2017 Aug 10;6(9):e1342024
pubmed: 28932646
Eur J Immunol. 2015 Aug;45(8):2171-82
pubmed: 26031799
Cell. 2018 Aug 23;174(5):1054-1066
pubmed: 30142344
Immunity. 2015 Aug 18;43(2):394-407
pubmed: 26287684
Cell. 2017 Mar 9;168(6):1086-1100.e10
pubmed: 28283063
Eur J Immunol. 2019 Jun;49(6):884-893
pubmed: 30892687
Immunol Rev. 2006 Dec;214:56-72
pubmed: 17100876
Cell Host Microbe. 2012 Oct 18;12(4):445-57
pubmed: 23084914
Trends Immunol. 2020 May;41(5):436-452
pubmed: 32223931
Haematologica. 2015 Jul;100(7):e257-60
pubmed: 25710455
Front Immunol. 2020 Feb 04;10:3111
pubmed: 32117199
Cell. 2017 Nov 2;171(4):795-808.e12
pubmed: 29056343
Haematologica. 2015 Apr;100(4):489-98
pubmed: 25596273
Biomed J. 2021 Apr;44(2):123-132
pubmed: 33849806
Nat Commun. 2019 May 14;10(1):2162
pubmed: 31089134
Immunity. 2014 Sep 18;41(3):354-365
pubmed: 25238093
J Immunol. 2020 Feb 15;204(4):1001-1011
pubmed: 31900341
Eur J Immunol. 2021 Apr;51(4):811-823
pubmed: 33300130
Immunity. 2021 Oct 12;54(10):2417-2432.e5
pubmed: 34453879
Blood. 2008 Aug 1;112(3):461-9
pubmed: 18650461
Front Immunol. 2022 Mar 10;13:836999
pubmed: 35359972
Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2402-7
pubmed: 21248224
Nat Rev Immunol. 2003 Apr;3(4):292-303
pubmed: 12669020
Curr Opin Immunol. 2021 Feb;68:28-33
pubmed: 32971468
Trends Immunol. 2013 Dec;34(12):573-82
pubmed: 24055329
Annu Rev Immunol. 2005;23:225-74
pubmed: 15771571
Cell Biol Int. 2008 Feb;32(2):188-97
pubmed: 17920947
J Exp Med. 2018 Jan 2;215(1):263-281
pubmed: 29222107
Gastroenterology. 2007 Aug;133(2):559-73
pubmed: 17681176
Nat Rev Immunol. 2015 Jul;15(7):415-28
pubmed: 26065585
Blood. 2013 Mar 21;121(12):2234-43
pubmed: 23327921
Front Immunol. 2019 May 07;10:861
pubmed: 31134050
Nat Immunol. 2019 Aug;20(8):980-991
pubmed: 31209406
J Exp Med. 2006 Apr 17;203(4):1033-43
pubmed: 16606675
Nat Commun. 2021 Oct 6;12(1):5841
pubmed: 34615883
Trends Immunol. 2001 Nov;22(11):633-40
pubmed: 11698225
Cancers (Basel). 2018 Nov 29;10(12):
pubmed: 30501078
Front Immunol. 2017 Mar 27;8:360
pubmed: 28396671
Curr Opin Immunol. 2019 Feb;56:100-106
pubmed: 30579240
J Exp Med. 2014 Mar 10;211(3):563-77
pubmed: 24516120
Cytometry B Clin Cytom. 2018 May;94(3):392-399
pubmed: 29244250
Eur J Immunol. 1975 Feb;5(2):117-21
pubmed: 1086218
Nat Rev Immunol. 2003 May;3(5):413-25
pubmed: 12766763
Nat Rev Immunol. 2021 Oct;21(10):616
pubmed: 34580448
Blood. 2014 Jul 31;124(5):812-21
pubmed: 24855210
Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):10961-6
pubmed: 20534450
Immunity. 2015 Aug 18;43(2):354-68
pubmed: 26231117
Immunity. 2018 Sep 18;49(3):464-476.e4
pubmed: 30193847
Elife. 2014 Oct 13;3:
pubmed: 25310240
J Immunol. 2014 Jan 15;192(2):741-51
pubmed: 24337742
Nature. 2009 Feb 5;457(7230):722-5
pubmed: 18978771
Curr Opin Immunol. 2016 Feb;38:75-85
pubmed: 26707651
Proc Natl Acad Sci U S A. 2015 Aug 25;112(34):10762-7
pubmed: 26243875
Immunity. 2021 Jun 8;54(6):1320-1337.e4
pubmed: 33945787
Immunity. 2016 May 17;44(5):1140-50
pubmed: 27178467
Front Immunol. 2013 Feb 01;4:15
pubmed: 23378843
Nat Immunol. 2016 Jun 21;17(7):790-4
pubmed: 27328009
Blood Adv. 2019 Nov 26;3(22):3674-3687
pubmed: 31765481
Immunity. 2005 Mar;22(3):295-304
pubmed: 15780987
Front Immunol. 2016 Jun 30;7:262
pubmed: 27446091
Nat Immunol. 2001 Oct;2(10):917-24
pubmed: 11577347
Immunol Rev. 2014 Sep;261(1):23-49
pubmed: 25123275
Front Immunol. 2017 May 15;8:535
pubmed: 28555134
J Exp Med. 2019 Sep 2;216(9):2221-2222
pubmed: 31387864
Blood Adv. 2017 Dec 14;1(27):2679-2691
pubmed: 29296921
Nat Immunol. 2017 Sep;18(9):995-1003
pubmed: 28759002
Immunity. 2013 Apr 18;38(4):769-81
pubmed: 23453631
Nat Immunol. 2016 Jan;17(1):76-86
pubmed: 26595888
Cell Rep. 2017 Oct 17;21(3):823-833
pubmed: 29045847
J Allergy Clin Immunol. 2016 Nov;138(5):1265-1276
pubmed: 27677386
Hepatology. 2022 Mar 4;:
pubmed: 35243668
Nat Rev Immunol. 2017 Nov;17(11):665-678
pubmed: 28804130
J Exp Med. 2018 Jan 2;215(1):249-262
pubmed: 29183988
Immunity. 2012 Jan 27;36(1):55-67
pubmed: 22261438
Nat Immunol. 2017 Sep;18(9):1004-1015
pubmed: 28759001
Nat Immunol. 2015 Oct;16(10):1044-50
pubmed: 26280998
Cell Res. 2021 May;31(5):554-568
pubmed: 33420427
J Immunol. 2007 Apr 15;178(8):4947-55
pubmed: 17404276
Cell Rep. 2016 Oct 4;17(2):436-447
pubmed: 27705792
Nat Immunol. 2021 Oct;22(10):1256-1267
pubmed: 34462601
Front Immunol. 2021 Apr 19;12:675169
pubmed: 33953732
Immunity. 1997 Oct;7(4):493-504
pubmed: 9354470
Immunity. 2019 Jul 16;51(1):104-118.e7
pubmed: 31128961
Trends Immunol. 2020 Oct;41(10):902-917
pubmed: 32917510

Auteurs

Michela Calvi (M)

Department of Medical Biotechnologies and Translational Medicine (BioMeTra), University of Milan, Milan, Italy.

Clara Di Vito (C)

Unit of Clinical and Experimental Immunology, IRCCS Humanitas Research Hospital, Milan, Italy.

Alessandro Frigo (A)

Department of Medical Biotechnologies and Translational Medicine (BioMeTra), University of Milan, Milan, Italy.

Sara Trabanelli (S)

Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Ludwig Institute for Cancer Research, Lausanne, Switzerland.

Camilla Jandus (C)

Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Ludwig Institute for Cancer Research, Lausanne, Switzerland.

Domenico Mavilio (D)

Department of Medical Biotechnologies and Translational Medicine (BioMeTra), University of Milan, Milan, Italy.
Unit of Clinical and Experimental Immunology, IRCCS Humanitas Research Hospital, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH